Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1/2 study of ziftomenib in relapsed or refractory acute myeloid leukemia
2023-510509-17-00Phase 2Authorised
- Sponsor
- Kura Oncology
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of ziftomenib in acute myeloid leukemia (AML) (6 arms), sponsored by Kura Oncology. Primary endpoints: Maximum tolerated dose, Recommended phase 2 dose and 3 more. Planned start Jun 2020; status: authorised.
02
Drugs
ziftomenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-510509-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510509-17-00.